Good morning :)
Place Order
Add to Watchlist

Brooks Laboratories Ltd

BROOKS Share Price

145.972.00% (-2.98)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹429 cr, stock is ranked 1,953

Stock is 4.14x as volatile as Nifty

BROOKS Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹429 cr, stock is ranked 1,953

Stock is 4.14x as volatile as Nifty

BROOKS Performance & Key Metrics

BROOKS Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-43.176.56
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
36.486.570.80%

BROOKS Analyst Ratings & Forecast

Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

BROOKS Company Profile

Brooks Laboratories Ltd. is a Contract Manufacturing Company. The Company manufacturers molecules in Injectables and Clavulanic Acid range in Tablets and Dry Syrups.

BROOKS Similar Stocks (Peers)

Compare with peers Compare with peers 

BROOKS Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
83.08
83.08
1Y Return
48.99%
48.99%
Buy Reco %
47.83
47.83
PE Ratio
51.54
51.54
1Y Return
11.06%
11.06%
Buy Reco %
71.43
71.43
PE Ratio
30.37
30.37
1Y Return
43.68%
43.68%
Buy Reco %
0.00
0.00
PE Ratio
1,234.42
1,234.42
1Y Return
45.39%
45.39%
Buy Reco %
0.00
0.00
PE Ratio
29.74
29.74
1Y Return
87.11%
87.11%
Buy Reco %
0.00
0.00
Compare with Peers

BROOKS Forecast

BROOKS Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

BROOKS

BROOKS

Income

Balance Sheet

Cash Flow

BROOKS Income Statement

BROOKS Income Statement

Loading...

Financial YearFY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue77.9991.9863.7780.4583.4483.47
Raw Materialssubtract51.7766.2847.4556.5990.6090.63
Power & Fuel Costsubtract2.703.993.231.73
Employee Costsubtract12.0416.8516.0010.09
Selling & Administrative Expensessubtract6.218.576.214.05
Operating & Other expensessubtract4.019.7520.0424.93
Depreciation/Amortizationsubtract7.147.357.031.771.601.60
Interest & Other Itemssubtract3.103.102.180.841.031.02
Taxes & Other Itemssubtract10.38-12.61-17.470.030.180.18
EPS-7.76-4.53-8.38-7.65-373.00-3.79
DPS0.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.00

BROOKS Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
FY 2016FY 2016

Annual report

PDF
FY 2015FY 2015

Annual report

PDF
 

BROOKS Stock Peers

BROOKS Past Performance & Peer Comparison

BROOKS Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CareLabs & Life Sciences Services

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Brooks Laboratories Ltd-43.136.56
Divi's Laboratories Ltd83.0813.410.44%
Syngene International Ltd51.545.41
Aarti Pharmalabs Ltd30.374.710.55%

BROOKS Stock Price Comparison

Compare BROOKS with any stock or ETF
Compare BROOKS with any stock or ETF
BROOKS
Loading...

BROOKS Holdings

BROOKS Shareholdings

BROOKS Promoter Holdings Trend

BROOKS Promoter Holdings Trend

Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 10.97%

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

BROOKS Institutional Holdings Trend

BROOKS Institutional Holdings Trend

Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has decreased by 2.17%

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

BROOKS Shareholding Pattern

BROOKS Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding52.62%9.90%0.48%0.05%36.95%

Sep 2024

Dec 2024

Jan 2025

Mar 2025

BROOKS Shareholding History

BROOKS Shareholding History

MarJunSepDec '24JanMar0.00%0.00%0.02%0.01%0.00%0.05%

Mutual Funds Invested in BROOKS

Mutual Funds Invested in BROOKS

No mutual funds holding trends are available

Top 1 Mutual Funds holding Brooks Laboratories Ltd


Funds (Top 1)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
9.7204%3.14%0.69%12/46 (-1)

Compare 3-month MF holding change on Screener

BROOKS Insider Trades & Bulk Stock Deals

BROOKS Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing BROOKS stock

smallcases containing BROOKS stock

Looks like this stock is not in any smallcase yet.

BROOKS Events

BROOKS Events

BROOKS Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

BROOKS has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

BROOKS Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

BROOKS has not given any dividends in last 5 years

BROOKS Dividends

BROOKS Dividends

Hmm, looks like data is unavailable here. Please come back after some time

BROOKS Stock News & Opinions

BROOKS Stock News & Opinions

Earnings
Brooks Laboratories reports consolidated net loss of Rs 1.46 crore in the March 2025 quarter

Net Loss of Brooks Laboratories reported to Rs 1.46 crore in the quarter ended March 2025 as against net loss of Rs 9.61 crore during the previous quarter ended March 2024. Sales rose 31.60% to Rs 23.32 crore in the quarter ended March 2025 as against Rs 17.72 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 9.97 crore in the year ended March 2025 as against net loss of Rs 19.59 crore during the previous year ended March 2024. Sales rose 3.86% to Rs 82.56 crore in the year ended March 2025 as against Rs 79.49 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales23.3217.72 32 82.5679.49 4 OPM %-5.36-53.78 --9.74-22.48 - PBDT-0.90-9.15 90 -8.19-17.79 54 PBT-1.28-9.61 87 -9.79-19.57 50 NP-1.46-9.61 85 -9.97-19.59 49 Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Brooks Laboratories standalone net profit rises 356.67% in the March 2025 quarter

Net profit of Brooks Laboratories rose 356.67% to Rs 1.37 crore in the quarter ended March 2025 as against Rs 0.30 crore during the previous quarter ended March 2024. Sales rose 31.60% to Rs 23.32 crore in the quarter ended March 2025 as against Rs 17.72 crore during the previous quarter ended March 2024. For the full year,net profit rose 99.35% to Rs 3.05 crore in the year ended March 2025 as against Rs 1.53 crore during the previous year ended March 2024. Sales rose 3.86% to Rs 82.56 crore in the year ended March 2025 as against Rs 79.49 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales23.3217.72 32 82.5679.49 4 OPM %6.782.14 -6.034.09 - PBDT1.940.76 155 4.833.33 45 PBT1.550.30 417 3.231.56 107 NP1.370.30 357 3.051.53 99 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Brooks Laboratories to table results

Brooks Laboratories will hold a meeting of the Board of Directors of the Company on 28 May 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Brooks Laboratories reports consolidated net loss of Rs 4.57 crore in the December 2024 quarter

Net Loss of Brooks Laboratories reported to Rs 4.57 crore in the quarter ended December 2024 as against net loss of Rs 3.88 crore during the previous quarter ended December 2023. Sales rose 76.78% to Rs 38.45 crore in the quarter ended December 2024 as against Rs 21.75 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales38.4521.75 77 OPM %-8.89-15.49 - PBDT-3.76-3.42 -10 PBT-4.55-3.85 -18 NP-4.57-3.88 -18 Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Brooks Laboratories to declare Quarterly Results

Brooks Laboratories will hold a meeting of the Board of Directors of the Company on 13 February 2025.Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Brooks Laboratories EGM scheduled

Brooks Laboratories announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 11 January 2025.Powered by Capital Market - Live

6 months agoCapital Market - Live
Corporate
Brooks Laboratories to conduct board meeting

Brooks Laboratories will hold a meeting of the Board of Directors of the Company on 11 December 2024Powered by Capital Market - Live

6 months agoCapital Market - Live
Earnings
Brooks Laboratories reports consolidated net loss of Rs 3.96 crore in the September 2024 quarter

Net Loss of Brooks Laboratories reported to Rs 3.96 crore in the quarter ended September 2024 as against net loss of Rs 1.64 crore during the previous quarter ended September 2023. Sales declined 14.51% to Rs 20.79 crore in the quarter ended September 2024 as against Rs 24.32 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales20.7924.32 -15 OPM %-16.40-4.52 - PBDT-3.53-1.20 -194 PBT-3.96-1.64 -141 NP-3.96-1.64 -141 Powered by Capital Market - Live

7 months agoCapital Market - Live
Corporate
Brooks Laboratories schedules board meeting

Brooks Laboratories will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live

7 months agoCapital Market - Live
Corporate
Brooks Laboratories to conduct AGM

Brooks Laboratories announced that the 22th Annual General Meeting (AGM) of the company will be held on 19 September 2024.Powered by Capital Market - Live

9 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Brooks Laboratories Ltd (BROOKS) today?

    The share price of BROOKS as on 1st July 2025 is ₹145.97. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Brooks Laboratories Ltd (BROOKS) share?

    The past returns of Brooks Laboratories Ltd (BROOKS) share are
    • Past 1 week: 0.80%
    • Past 1 month: -2.01%
    • Past 3 months: 31.80%
    • Past 6 months: -20.56%
    • Past 1 year: 72.03%
    • Past 3 years: 73.38%
    • Past 5 years: 395.36%

  3. What are the peers or stocks similar to Brooks Laboratories Ltd (BROOKS)?
  4. What is the market cap of Brooks Laboratories Ltd (BROOKS) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Brooks Laboratories Ltd (BROOKS) is ₹429.99 Cr as of 1st July 2025.

  5. What is the 52 week high and low of Brooks Laboratories Ltd (BROOKS) share?

    The 52-week high of Brooks Laboratories Ltd (BROOKS) is ₹198.86 and the 52-week low is ₹82.

  6. What is the PE and PB ratio of Brooks Laboratories Ltd (BROOKS) stock?

    The P/E (price-to-earnings) ratio of Brooks Laboratories Ltd (BROOKS) is -43.13. The P/B (price-to-book) ratio is 6.56.

  7. Which sector does Brooks Laboratories Ltd (BROOKS) belong to?

    Brooks Laboratories Ltd (BROOKS) belongs to the Health Care sector & Labs & Life Sciences Services sub-sector.

  8. How to buy Brooks Laboratories Ltd (BROOKS) shares?

    You can directly buy Brooks Laboratories Ltd (BROOKS) shares on Tickertape. Simply sign up, connect your demat account and place your order.